RxDoctor Payments Data

Cynthia Ragsdale

Family · Albany, GANPI 1639559149

Payments from drug & device makers

$7,285in general payments, 2019–2025

Across 319 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$925
  • AbbVie$768
  • Johnson & Johnson$615
  • Boehringer Ingelheim$468
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$322
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,16198%
  • Education$1252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,285 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$18,850
Medicare patients
182
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase32$74,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$36,934
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$13,112
SymbicortBudesonide/Formoterol Fumarate20$4,621
Omeprazole122$1,216
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl71$1,128
Albuterol Sulfate HfaAlbuterol Sulfate43$1,118
Lubiprostone16$1,100
Famotidine75$945
Sucralfate32$845
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl29$406
Dicyclomine Hcl40$402
Montelukast Sodium29$299
Ondansetron OdtOndansetron27$211
Pantoprazole Sodium15$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$768$74,98132 claims
GSKTrelegy Ellipta$1,129$36,93446 claims
AstraZenecaBreztri Aerosphere, Symbicort$925$17,73337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →